|
Braeburn License (Details Textual) (USD $)
|
1 Months Ended | 3 Months Ended |
|---|---|---|
|
Dec. 31, 2012
|
Mar. 31, 2013
|
|
| Braeburn License (Textual) [Abstract] | ||
| License revenue, recognized | $ 3,750,000 | |
| Deferred contract revenue | 14,375,000 | 10,625,000 |
|
Collaborative Arrangement, Co-promotion [Member]
|
||
| Braeburn License (Textual) [Abstract] | ||
| Non-refundable up-front payment | 15,750,000 | |
| License and services revenue | 15,000,000 | |
| Milestone payment | 50,000,000 | |
| Additional amount received upon achievement of sales milestones | 130,000,000 | |
| Additional amount in regulatory milestones | 35,000,000 | |
| Potential milestone payments | 75,000,000 | |
| Estimated revenue recognition period for upfront payment | 12 months | |
| Revenues to be recognized per month for upfront payment | 1,250,000 | |
| License revenue, recognized | 4,400,000 | |
| Deferred contract revenue | $ 10,600,000 | |
| Maximum receipt time for milestone payment | 10 days | |
| Development committee disbandment period after specified product transfer date | 6 years |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Development committee disbandment period after specified product transfer date. No definition available.
|
| X | ||||||||||
|
- Definition
Estimated revenue recognition period for upfront payment. No definition available.
|
| X | ||||||||||
|
- Definition
License and services revenue net. No definition available.
|
| X | ||||||||||
|
- Definition
Maximum amount eligible to be received on achievement of regulatory milestone. No definition available.
|
| X | ||||||||||
|
- Definition
Maximum amount eligible to be received on achievement of sales milestone. No definition available.
|
| X | ||||||||||
|
- Definition
Maximum receipt time for milestone payment. No definition available.
|
| X | ||||||||||
|
- Definition
Minimum amount allocated to launch commercialize and continue development of specific product. No definition available.
|
| X | ||||||||||
|
- Definition
Revenue recognition using milestone method Fda approval achievement amount. No definition available.
|
| X | ||||||||||
|
- Definition
Revenues to be recognized per month for upfront payment. No definition available.
|
| X | ||||||||||
|
- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|